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Abstract
Rats lesioned with 6-hydroxydopamine (6-OHDA) as neonates exhibit behavioral and
neurochemical abnormalities in adulthood that mimic Lesch-Nyhan disease, schizophrenia and
other developmental disorders of frontostriatal circuit dysfunction. In these animals, a latent
sensitivity to D1 agonists is maximally exposed by repeated administration of dopamine agonists
in the post-pubertal period (D1 priming). In neonate-lesioned, adult rats primed with SKF-38393,
we found selective, persistent alterations in the morphology of pyramidal neuron apical dendrites
in the prelimbic area of the medial prefrontal cortex (mPFC). In these animals, dendrite bundling
patterns and the typically straight trajectories of primary dendritic shafts were disrupted, whereas
the diameter of higher-order oblique branches was increased. Although not present in neonate-
lesioned rats treated with saline, these morphological changes persisted at least 21 days after
repeated dosing with SKF-38393, and were not accompanied by markers of neurodegenerative
change. A sustained increase in phospho-ERK immunoreactivity in wavy dendritic shafts over the
same period suggested a relationship between prolonged ERK phosphorylation and dendritic
remodeling in D1-primed rats. In support of this hypothesis, pretreatment with the MEK1/2-
ERK1/2 pathway inhibitors PD98059 or SL327, prior to each priming dose of SKF-38393,
prevented the morphological changes associated with D1 priming. Together, these findings
demonstrate that repeated stimulation of D1 receptors in adulthood interacts with the
developmental loss of dopamine to profoundly and persistently modify neuronal signaling and
dendrite morphology in the mature prefrontal cortex. Furthermore, sustained elevation of ERK
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activity in mPFC pyramidal neurons may play a role in guiding these morphological changes in
vivo.
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INTRODUCTION
Dendrites receive multiple and diverse synaptic inputs, processing and integrating them into
signals that convey information to the soma and axon. Neuronal identity largely dictates
basic dendrite structure, but environmental signals further shape dendrites during
development and in adulthood (Miller and Kaplan, 2003). In a reciprocal manner, dendritic
morphology impacts spatial and temporal neurotransmission by affecting the propagation
and patterning of action potentials (Mainen and Sejnowski, 1996; Vetter et al., 2001).
Accordingly, the structural remodeling of dendrites and their spines is thought to coordinate
with physiological processes associated with neuroadaptation, such as learning and memory
(Lamprecht and LeDoux, 2004) and behavioral sensitization to psychostimulants (Robinson
and Kolb, 2004).
The neonatal administration of 6-OHDA to rats results in behavioral, functional and
neurochemical effects that are different from those of rats lesioned with 6-OHDA in
adulthood (Breese et al., 2005). One consequence of neonatal lesioning is a latent behavioral
sensitivity to D1 dopamine receptor agonists that is only maximally expressed following
repeated, post-pubertal dopamine agonist administration (Criswell, 1989). This
phenomenon, known as “D1-priming”, results in a profound activation of locomotor and
stereotypical behaviors in response to doses of the D1 agonist SKF-38393 that are
behaviorally ineffective in control rats. While these agonist-induced hyperactive behaviors
abate within a few hours of dosing, the increased sensitivity to a subsequent agonist
challenge lasts for at least 6 months (Breese et al., 1984; Criswell et al., 1989). Importantly,
neonate-lesioned rats dosed repeatedly with saline in early adulthood exhibit normal
baseline activity and low to moderate behavioral sensitivity to a single challenge with
SKF-38393. These findings suggest that, when superimposed upon the developmental
effects of reduced dopamine, repeated D1 agonist exposure in neonate-lesioned rats
stimulates long-lasting neuroadaptive changes that mediate the profound behavioral
sensitivity of these animals.
Recently, we demonstrated the remarkably persistent phosphorylation of ERK1/2 and CREB
in medial prefrontal cortex (mPFC) neurons of D1-primed rats (Papadeas et al., 2004), and
proposed that such sustained activation of neuronal signaling may promote enduring
neuroplastic changes in this region. In the current report, we describe modifications in the
morphology of pyramidal neuron apical dendrites that accompany prolonged ERK
phosphorylation in the mPFC of these animals. Furthermore, by blocking these
morphological changes with MEK1/2 inhibitors administered in vivo, evidence is provided




6-hydroxydopamine hydrobromide (6-OHDA; ICN, Irvine, CA) was dissolved in saline
containing 0.5% ascorbic acid. Desipramine HCl (Sigma-Aldrich, St. Louis, MO) and
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SKF-38393 (2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benazepine HCl; Sigma-
Aldrich), were dissolved in saline. SL327 (α-[amino[(4-aminophenyl)thio]methylene]-2-
(trifluoromethyl) benzeneacetonitrile; a gift from Bristol-Myers-Squibb Company,
Princeton, NJ) and PD98059 (2′-amino-3′-methoxyflavone; Calbiochem, La Jolla, CA) were
dissolved in dimethylsulfoxide (DMSO) and further diluted in sterile saline (pH 7.3) to a
concentration of 1% DMSO immediately prior to intracerebroventricular (icv) infusion (Gu
et al., 2001). For intraperitoneal (ip) administration, SL327 was dissolved in DMSO at 2 mg/
ml as described by Atkins et al. (1998). Kainic acid (Sigma-Aldrich, St. Louis, MO) was
dissolved in saline at 1 mg/ml. Drug dosages are provided below.
Experimental Design
All animals were treated and used in accordance with the NIH Guide for the Care and Use
of Laboratory Animals with approval from the Institutional Animal Care and Use
Committee at UNC-Chapel Hill. Sprague-Dawley rats were bred in-house from stock
obtained from Charles River Labs, Raleigh, NC. To lesion dopaminergic neurons, rats were
injected intracisternally with 6-OHDA (neonate-lesioned) on postnatal day (PND) 4 as
previously described (Papadeas et al., 2004). Sham-lesioned rats were injected with saline.
In both groups, noradrenergic neurons were protected by administering a single dose of
desmethylimipramine (20 mg/kg ip) 1 hour prior to lesioning. Both sexes were used for the
present study, balanced with the same number of controls of each sex. There were no gender
differences in locomotor behavior or morphological findings (data not shown).
A timeline of experimental procedures is provided in Fig. 1. Beginning on PND 42, rats
were administered four ip injections of the selective, partial D1 agonist SKF-38393 (3 mg/
kg) or saline vehicle at weekly intervals (Fig. 1A, Basic Protocol). The use of SKF-38393
for this study is based on a significant body of data from our laboratory relating to the
behavioral effects of this agonist in the neonate lesioned rat (for example, see Breese et al.,
1985;Criswell et al., 1989;Criswell et al., 1990;Moy et al., 1994;Papadeas et al., 2004),
including a previous study demonstrating higher efficacy of SKF-38393 in producing
locomotor activation and lower potency to produce self-injurious behavior compared to a
selective, full D1 agonist (Johnson et al., 1992). In addition, this dose of SKF-38393 does
not stimulate locomotor activity or induce behavioral sensitization in sham-lesioned rats
(Criswell et al., 1989;Moy et al., 1994;Papadeas et al., 2004, and see below). As described
previously (Papadeas et al., 2004), behavioral sensitivity to SKF-38393 administration (D1
priming) was monitored following each dose, and neonate-lesioned rats exhibited a
progressive increase in agonist-mediated locomotor activity culminating in ≥80,000 total
horizontal counts/180 min following the final SKF-38393 treatment. Activity counts of
neonate-lesioned rats treated with saline and sham-lesioned rats treated with either saline or
SKF-38393 typically ranged from 1500 to 3000 total counts/180 min. It is important to note
that the spontaneous locomotor activity of D1-primed rats is similar to that of the controls. In
other words, neonate-lesioned adults that have already received repeated doses of
SKF-38393 are behaviorally supersensitive to the locomotor activating effects of a
subsequent injection of the D1 agonist, but they do not exhibit locomotor hyperactivity when
injected with saline (1500 to 3000 activity counts/180 min), nor in the absence of
manipulation in the home cage (data not shown). Relative to saline-treated rats, the weekly
episodes of drug-induced hyperactive behavior did not affect the physical appearance, body
weight, or weight gained per week of lesioned, SKF-38393-treated rats (data not shown).
Some rats were surgically implanted with icv cannulae before agonist dosing in preparation
for administering inhibitors of MEK1/2 (Fig. 1B, MEK inhibitor preinfusions). At PND 35,
drug-naïve neonate-lesioned and sham-lesioned rats were anesthetized with sodium
pentobarbital (50 mg/kg, ip) and sterotaxically implanted with a 26-gauge stainless steel
cannula into the right lateral ventricle (from bregma; anteroposterior, -0.8 mm; mediolateral,
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-1.5 mm; dorsoventral, -2 mm; according to Paxinos and Watson (1998). The cannula was
fixed in place with dental cement and the animals were allowed to recover for 7 days before
initiating the D1 agonist treatment. Beginning on PND 42, animals received icv infusions of
PD98059 (0.38 nmol/μl), SL327 (1 nmol/μl) or vehicle (1% DMSO in sterile saline), prior
to each weekly systemic dose of SKF-38393. A 32-gauge stainless steel microinjector
needle and variable-rate syringe pump were used to inject a volume of 2 μl over 5 min
intraventricularly. The needle was allowed to remain in place for 1 min to reduce backflow
of the solution along the injection track. After 30 min, D1 agonist injections were followed
by behavioral testing as described above.
In a third experiment (Fig. 1C, AAV-GFP transduction), prelimbic neurons of some animals
were transduced in vivo with green fluorescent protein (GFP) prior to initiating the priming
regimen with SKF-38393. This allowed us to directly visualize the changes in dendritic
structure caused by D1-priming when brain sections were later examined microscopically.
Preparation and infusion of the adeno-associated virus (AAV) vector construct, with
expression of GFP driven by a hybrid chicken beta-actin promoter (AAV-GFP), has been
described (McCown et al., 2006). Briefly, drug-naive neonate-lesioned and sham-lesioned
rats were anesthetized on PND 30 with sodium pentobarbital as described above and placed
in a Kopf stereotaxic apparatus. A 33-gauge injector was lowered into the prelimbic area
(from bregma; anteroposterior, 3.2 mm; mediolateral, -0.6 mm; dorsoventral, -2.0 mm;
according to Paxinos and Watson, 1998). Using a Sage syringe pump (Thermo Electron
Corporation, Beverly, MA), 2.0 μl of recombinant vector (titer, 1 × 1013 viral particles/ml)
was microinfused over a 20 min period into the mPFC. The injector was left in place for 3
min post-infusion to allow diffusion from the site and to prevent backflow of solution. The
incision was closed and animals were allowed 12 days to recover from the infusions before
the D1 agonist dosing was initiated. AAV-GFP-transduced cells continue to express GFP for
several months in vivo (Klein et al., 2002). In the present study, vivid GFP expression was
evident at day 7 after the final weekly treatment with SKF-38393 (approximately 40 days
after viral-mediated transfer).
In the fourth experiment, rats that had been transduced with AAV-GFP at 30 days of age
received systemic injections of SL327 (100 mg/kg, ip) prior to each dose of D1 agonist (Fig.
1D, AAV-GFP + systemic MEK inhibitor). Systemic administration of this blood-brain
barrier-permeable MEK inhibitor substantiated the results we obtained with icv infusion of
SL327 and furthermore, obviated the need for dual surgeries for cannula implantation and
intracortical viral injections. SL327 was administered 30 min prior to the weekly
SKF-38393 injections and behavioral testing was performed as described above for four
weeks.
In all studies, rats were euthanized on PND 70 (7 days after the final priming treatment) by
transcardial perfusion with 4% paraformaldehyde as previously described (Papadeas et al.,
2004) or by decapitation. One exception was a subset of animals in the Basic Protocol (3-4
per group), perfused on day 84 (21 days after the final agonist dose) to assess the persistence
of the morphological effects.
Antibody characterization
Affinity-purified, polyclonal anti-tyrosine hydroxylase (TH) antibody (#657012,
Calbiochem, San Diego, CA) was raised in rabbits against purified, SDS-denatured rat
pheochromocytoma TH enzyme. This antibody recognizes a single band of approximately
60 kDa on Western blots of rat striatum or PC-12 cell extracts (Haycock, 1989). Specificity
for tyrosine hydroxylase by immunohistochemistry is demonstrated by the loss of
immunoreactivity in rat striatum after lesioning of dopaminergic afferents with 6-OHDA
(Papadeas et al., 2004).
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Anti-phospho-p44/42 MAP kinase (Thr202/Tyr204) (#9106, Cell Signaling Technology,
Beverly, MA) is a mouse monoclonal antibody raised to a synthetic keyhole limpet
hemocyanin (KLH)-conjugated phosphopeptide corresponding to amino acid residues
198-208 of human p44 MAP kinase (ERK1), containing the Thr202/Tyr204 phosphorylation
sites (Thr-Gly-Phe-Leu-pThr-Glu-pTyr-Val-Ala-Thr-Arg-Trp-Tyr-Arg-Cys). According to
Cell Signaling Technology, the antibody reacts specifically with as little as 50 pg of
phosphorylated ERK and does not cross-react with up to 4 μg of nonphosphorylated ERK by
Western blotting. It selectively recognizes two distinct bands at approximately 44 kDa and
42 kDa corresponding to ERK1 and ERK2, respectively (per the manufacturer and our
previous data, not shown). As immuohistochemical controls in the present study, a 10-fold
(w/w) excess of phosphorylated or non-phosphorylated immunizing peptide (#ab5255,
Abcam, Cambridge MA) was preadsorbed with the antibody overnight (with gentle shaking
at 4°C) prior to labeling tissue sections by the standard immunohistochemical and antigen
retrieval protocols described below. No signal was detected when the antibodies were
preadsorbed with phosphorylated peptide prior to staining sections by the standard protocol
(not shown) or by antigen retrieval (Fig. 5C, Phosphopeptide). On the other hand, the non-
phosphorylated peptide failed to block immunohistochemical labeling with the antibody,
either on sections stained by the standard method (not shown), or using antigen retrieval
(Fig. 5C’, Non-phosphopeptide). Thus the antibody recognizes the phosphorylated, but not
the non-phosphorylated, form of ERK1/2. Further controls were run by staining sections in
the absence of primary antibody under standard and antigen retrieval conditions; phospho-
ERK staining was not observed and the results appeared similar to that seen in Fig. 5C,
Phosphopeptide. It should be noted that Cell Signaling Technology no longer recommends
product #9106 for immunohistochemistry, advising that newer products may be more
suitable for this procedure.
The mouse monoclonal anti-MAP2 antibody (clone AP20; #MAB3418, Chemicon,
Temecula, CA) was raised to purified MAP2 from bovine brain. On Western blots this
antibody recognizes two closely associated bands of approximately 300 kDa, corresponding
to the high molecular weight (HMW) forms of MAP2 (MAP2a and MAP2b). It does not
react with the low molecular weight (LMW) form known as MAP2c, or with MAP1 (Binder
et al., 1986; Kalcheva et al., 1994; Blanchart et al., 2006; this study). The AP20 clone has
been used extensively to detect MAP2 in rat brain sections and specifically labels neuronal
dendrites and somata (see for example, Minger et al., 1998; Bury and Jones, 2002).
Immunohistochemical controls for the present study consisted of rat brain coronal sections
stained in the absence of primary antibody; no tissue labeling was apparent with the use of
either biotinylated or fluorescence-conjugated secondary antibody (see below; data not
shown).
A mouse monoclonal antibody to αII-spectrin (α-fodrin, clone AA6; #mab1622, Chemicon)
was generated to the purified membranes of lysed, enucleated chicken red blood cells.
According to the manufacturer, it is specific for the 240 kDa full-length α-spectrin protein
found in all mammalian nonerythroid cells, and recognizes α-spectrin breakdown products
(SBDPs) generated through cleavage by caspase (150 kDa, 120 kDa) and calpain (150 kDa).
Several studies have utilized this product to characterize caspase and calpain activation in rat
cortex (Rau et al., 2003; Carloni et al., 2004; Calon et al., 2005) and other tissues.
The mouse monoclonal anti-β-actin antibody (clone AC-15; #A5441, Sigma-Aldrich) was
generated to a slightly modified synthetic peptide corresponding to the N-terminus of
cytoplasmic β-actin (Acetyl-Asp-Asp-Asp-Ile-Ala-Ala-Leu-Val-Ile-Asp-Asn-Gly-Ser-Gly-
Lys), coupled to KLH. It recognizes a single band at 42-45 kDa in a variety of tissues (per
the manufacturer). Its use as a reagent to normalize protein loading in Western blotting has
been characterized (Liao et al., 2000).
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Immunohistochemistry (IHC) and Western blotting (WB)
Immunohistochemical staining methods were performed as previously described (Papadeas
et al., 2004) on 40 μm free-floating coronal vibratome sections. In some cases, adjacent
sections were mounted and stained with 0.1% cresyl violet to study the cytoarchitecture.
Tyrosine hydroxylase immunoreactivity (1:4000 for IHC) was determined to establish the
extent of 6-OHDA lesioning (not shown). Anti-phospho-p44/42 MAP kinase (1:500) was
used to detect phospho-ERK. For qualitative evaluation of phospho-ERK staining in
dendrites, antigen retrieval was performed to enhance phospho-ERK1/2 staining in the
mPFC. The free-floating tissue sections were incubated at 70°C in 10 mM sodium citrate
buffer, pH 8.5 for 30 minutes, then washed once in 0.1M phosphate buffered saline, pH 7.4
(PBS) prior to immunostaining. Other sections were processed for phospho-ERK (1:500)
without antigen retrieval for quantitative evaluation by cell counting. All TH- and phospho-
ERK-stained sections were processed using Vectastain Elite ABC kits (rabbit IgG,
#PK-6101; mouse IgG, #PK-6102; Vector Laboratories, Burlingame, CA) per the
manufacturer’s instructions with immunochemical detection using nickel-cobalt
intensification of the 3,3′-diaminobenzidine (DAB) reaction product. MAP2A and B were
detected using the monoclonal anti-MAP2 antibody (1:500) by DAB IHC (performed with
the Vectastain Elite kit as described above) and by immunofluorescence. For fluorescence
IHC, free-floating tissue sections were incubated overnight at 4°C with anti-MAP2,
followed by incubation in Molecular Probes AlexaFluor 594-conjugated goat anti-mouse
secondary antibody (1:500; #A-11032, Invitrogen, Carlsbad, CA) for 45 min at 4°C with
agitation.
For Western blotting, brains were rapidly removed immediately following decapitation, and
the mPFC was dissected on ice, quickly frozen, and stored at -80°C until use. Tissues were
homogenized by sonification in solubilization buffer (10 mM Tris-HCl, 50 mM NaCl, 1%
Triton X-100, 30 mM sodium pyrophosphate, 50 mM NaF, 5 nM ZnCl2, 100 μM Na3VO4, 1
mM DTT, 5 nM okadaic acid, 2.5 ng/ml aprotinin, 2.5 ng/ml pepstatin, and 2.5 ng/ml
leupeptin). Insoluble material was removed by centrifugation (13,000 rpm for 20 min at
4°C), and protein concentration determined using a BCA protein assay kit (Pierce, Rockford,
IL). Samples were mixed with Novex Tris-glycine SDS sample buffer (San Diego, CA)
containing 5% 2-mercaptoethanol and heated to 90°C for 3 min. Aliquots of 20 μg of
protein/lane were separated on Novex 8-16% gradient Tris-glycine gels under reducing
conditions. Loading concentrations were based on pilot immunoblots (not shown) to
determine densitometric linearity under the detection conditions described below. Proteins
were transferred to polyvinylidene difluoride membranes (Immobilon-P, Millipore, Bedford,
MA), rinsed 3 times in PBS for 5 min, and incubated in Odyssey Blocking Buffer (LI-COR
Biosciences, Lincoln, NE) for 1 hour. Proteins were detected using one of the following:
anti-MAP2 antibody (1:500), anti-α-spectrin antibody (1:1000), or anti-β-actin antibody
(1:5000), diluted in 50% Odyssey Blocking Buffer in PBS containing 0.1% Tween-20.
Binding of the primary antibodies to their respective proteins was detected using Odyssey
IRDye 800CW-conjugated goat anti-mouse IgG (1:15,000; #926-32210, LI-COR) or
Odyssey IRDye 680-conjugated donkey anti-mouse IgG (1:15,000: #926-32222, LI-COR).
Fluorescent signals were detected using the Odyssey Infrared Imaging System (LI-COR
Biosciences). Average integrated signal intensity measurements were calculated using
Odyssey image analysis software after normalizing to β-actin.
Image acquisition and analysis
Immunohistochemical sections were analyzed by light microscopy using an Olympus BX50
microscope outfitted with a Sony DCX-390 video camera. Light levels were normalized to
preset values to ensure fidelity of the data acquisition. Cell counts were collected directly
while viewing in a single optical plane with a 20X objective as described previously
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(Papadeas et al., 2004) for phospho-ERK immunoreactivity and cresyl violet-stained
sections. In the latter, neurons were identified by their larger size and the presence of
prominent cresyl violet-stained cytoplasm and euchromatin in the nucleus. Although these
criteria may exclude some small neurons, most non-neuronal cells are eliminated from
counting. Cortical thickness and laminar measurements were taken from grayscale images of
cresyl violet-stained sections at a magnification of 8X, using the straight-line measure
function in ImageJ v1.37. Cortical laminae were estimated on the basis of characteristic
cytoarchitectonic landmarks as described by Van Eden and Uylings (1985), and Zilles and
Wree (1995). Measurements of layers I - VI were summed to obtain an estimate of total
cortical thickness. For MAP2 analyses, 8-bit grayscale images spaced approximately 250
μm apart were collected in layers II/III and V of mPFC. Six samples were obtained from
each of four different sections per animal. The area fraction of MAP2 immunostained
components was estimated using ImageJ software v1.34s. A grayscale morphology plugin
(available at http://rsb.info.nih.gov/ij/plugins/gray-morphology.html) was used to apply a
closing operator with an arbitrary radius of 6 pixels to each of the digitized images. This
enabled us to focus on larger MAP2-positive linear elements (primarily first order dendritic
processes) while omitting MAP2-stained somata and other features. The images were held to
a consistent threshold such that MAP2-stained dendrites were black and the background was
white. Threshold levels were individually set to ensure all MAP2-stained dendrites were
identified and image analysis was performed using the ‘Analyze Particles’ function in Image
J. Values were averaged for each animal, and means determined across all animals within a
treatment group. Statistical comparisons between groups were carried out with ANOVA.
Where appropriate, post-hoc comparisons between groups were performed using a Fisher’s
PLSD test. Representative light microscopic images for publication were adjusted for color,
brightness and contrast in Adobe Photoshop v5.0 and assembled in Adobe Illustrator v9.0.
Confocal imaging was performed at the Michael Hooker Microscopy Center at UNC-Chapel
Hill using a Zeiss Axiovert LSM510 laser confocal microscope equipped with argon (488
nm) and HeNe (543) lasers. Images were processed using Zeiss LSM Image Browser and
Adobe Photoshop software. MAP2 immunofluorescence and dual-label MAP2 and GFP
fluorescence images for qualitative assessment were reconstructed from a minimum of three
consecutive steps in a Z-series taken at 1 μm intervals through the section of interest using a
40x objective. Images were centered on layer II/III of the prelimbic cortex and included
portions of layers I and V (see Fig. 2I). To measure parameters of GFP-positive dendrites,
projected stacks of ten such images were analyzed using ImageJ v1.37c. There were no
differences in the total number of visible primary shafts or dendrite branches between the
groups. Dendrite lengths were traced with a mouse-driven cursor on the computer screen
along their visible distance until they bifurcated or left the visible field. In order to control
for slight differences in the positioning of photomicrographs, segments with end-to-end
lengths shorter than 50 μm and longer than 300 μm were excluded. Curvilinear lengths were
measured using the freehand utility, and end-to-end lengths were measured with the straight-
line function in ImageJ. The linearity index (LI) was calculated as the ratio of curvilinear
length to the distance between ends as described by Demyanenko et al. (1999). Dendrite
diameters, measured using the ImageJ straight-line function, represented an average of two
to three measurements spaced evenly along each visible segment. Most of the oblique
dendrites that were visible in this layer appeared to be secondary or tertiary branches of
pyramidal neurons, although some of these processes might have arisen from the few non-
primary neurons that expressed GFP. Length and diameter measurements are expressed in
micrometers as the mean ± S.E.M. of 3 to 6 rats per group. Total number of length
measurements: primary shafts, 20-114 dendrites per rat yielding a total of 192 -213 dendrites
per treatment group; layer I branches, 13-68 per rat, 126-204 per group; layer II/III oblique
branches, 10-29 per rat, 57 to 65 per group; layer V oblique branches, 10-18 per rat, 40-41
per group. Total diameter measurements: primary shafts, 20-87 per rat, 155-219 per group;
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layer I branches, 84-137 per rat, 366-421 per group; layers II/III and V oblique branches,
30-78 per rat, 115-209 per treatment group. Statistical comparisons between treatment
groups were carried out with ANOVA with Fisher’s PLSD. Representative confocal
microscopic images for publication were adjusted for color, brightness and contrast in Zeis
LSM Image Browser v3.2.0.115 and assembled in Adobe Illustrator v9.0.
RESULTS
D1-sensitized rats exhibit altered MAP2 immunostaining in medial prefrontal cortex
In adult rats that have been lesioned with 6-OHDA as neonates, repeated weekly
administration of SKF-38393 (3 mg/kg ip) results in behavioral sensitization to the
locomotor activating effects of selective D1 agonists. In these “D1-primed” animals, a
challenge dose of SKF-38393 elicits enhanced ambulatory and stereotypical behaviors, even
when administered months later (Criswell et al., 1989; Criswell et al., 1990). This behavioral
activation by SKF-38393 is transient (lasting approximately 3 hours post-injection), and in
the absence of drug administration, spontaneous locomotor activity in adults is similar to
that of sham-lesioned rats. Sham-lesioned rats do not exhibit locomotor activation following
acute SKF-38393 injections at this dose, nor do they become behaviorally sensitized or
primed to the agonist with repeated systemic administration (Criswell et al., 1989). Not
surprisingly then, when MAP2A/B immunohistochemistry was performed on day 7 after the
basic treatment protocol, dendritic MAP2 staining profiles were similar in all sham-lesioned
rats whether they were treated with SKF-38393 (Sham-SKF) or with saline (Sham-Sal). In
mPFC of these animals, MAP2 antibodies stained apical dendrites of layers II/III and V
pyramidal neurons intensely (Fig. 2A & B). First-order dendritic shafts were long and
straight, and traversed from deeper layers of the cortex to the pial surface in well-delineated
bundles, in agreement with descriptions by Gabbot and Bacon (1996). Likewise, day 7 tissue
sections from neonate-lesioned rats injected repeatedly with saline in adulthood (Les-Sal)
demonstrated classic mPFC MAP2 profiles that were indistinguishable from those of sham-
lesioned animals (Fig. 2C). On the other hand, D1 priming of neonate-lesioned rats by
repeatedly injecting SKF-38393 during adulthood (Les-SKF) resulted in MAP2-stained
apical dendritic processes that were shorter and bent, and bundling was far less prominent
(Fig. 2D). In Les-SKF animals, immunostaining in the neuropil throughout mPFC cortical
layers II through VI was attenuated relative to sham-lesioned rats, and layer I was frequently
stained more intensely than deeper layers. Although it is difficult to discern in Fig. 2D, the
border lying between layers I and II/III was more jagged in Les-SKF rats than the typically
straight, even margin of the sham-lesioned groups. At higher magnification in layer II/III
(Fig. 2E), Les-SKF dendritic bundles containing at most 2 to 3 visible shafts were observed,
and apical dendrites appeared truncated or discontinuous with obvious deviations from the
normal straight path. Sections from lesioned rats sacrificed 21 days after the final
SKF-38393 treatment (Fig. 2F) were virtually indistinguishable from day 7 sections, with
dendritic profiles that continued to course non-uniformly toward cortical layer I.
Immunofluorescence staining revealed several additional aspects of anti-MAP2 labeling that
had been less apparent with the DAB staining method. Using confocal microscopy to
examine the neuropil, small punctuate structures and fine processes consistent with oblique
dendrites were observed in layer II/III of Sham-Sal, Sham-SKF and Les-Sal rat mPFC
(Sham-SKF, Fig. 2G; Sham-Sal and Les-Sal are not shown). Compared with the fine fibrous
arrangement of neuropil in these control groups, the layer II/III neuropil of Les-SKF rats
appeared more coarsely textured, with larger punctae and thicker oblique branches (Fig.
2H). At the interface of cortical layers I and II/III, second and third order dendritic branches
of pyramidal neurons diverged from the primary shafts and could be followed for some
distance into the neuropil of mPFC layer I in Sham-Sal, Sham-SKF and Les-Sal rats. In the
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mPFC of Les-SKF rats however, MAP2 immunostained branches appeared thickened and
truncated as they diverged and penetrated layer I (Fig. 2H, arrowheads).
The pattern of straight, roughly equidistant parallel bundles of first order apical dendrites is
distinctive of pyramidal neurons in the cortex. To determine if the disruption of MAP2
immunostaining by D1 priming was representative of a widespread effect, cortical regions
throughout the brain were examined. With the exception of the anterior cingulate area that
caudally adjoins the prelimbic mPFC (not shown), cortical pyramidal neuron dendritic
profiles appeared normal throughout as exemplified by MAP2 staining in the visual cortex
(Fig. 2J). Likewise, inspection of hippocampal subregions revealed no changes in MAP2
dendritic profiles with D1 priming (not shown).
Neural insults, such as traumatic brain injury, oxygen-glucose deprivation, and NMDA-
dependent excitotoxicity, are frequently accompanied by calcium-dependent proteolysis of
MAP2 and other cytoskeletal proteins (Czogalla and Sikorski, 2005). Loss of MAP2 protein
by proteolysis might thus explain the diminished DAB immunohistochemical staining in the
neuropil of the D1-supersensitive mPFC, as well as the fragmented appearance of stained
apical dendritic processes. In order to quantitatively assess MAP2 protein levels, the same
antibodies that were used to label MAP2A/B immunohistochemically were applied to
Western blots of microdissected mPFC. The results revealed a characteristic broad band or
closely associated doublet of approximately 300kD consistent with MAP2A/B (Fig. 3A).
Fainter bands of increased electrophoretic mobility presumably represented MAP2
proteolytic degradation products (Quinlan and Halpain, 1996a). After normalization to β-
actin, average integrated signal intensity measurements for 300kD MAP2 were found to be
similar across all four treatment groups (F(3,14) = 0.726, p = 0.55). Likewise, actin-
normalized measures of the total remaining lower molecular weight bands in each lane were
not different (F(3,14) = 0.263, p = 0.85). Thus while MAP2 immunoreactivity in histological
sections appeared reduced, no loss of total levels of MAP2 protein was detected on Western
blots, and there was no evidence of enhanced MAP2 proteolysis. To substantiate the latter
findings, we immunoblotted Sham-Sal and Les-SKF mPFC lysates for αII-spectrin (α-
fodrin). Accumulated spectrin breakdown products (SBDPs) of 145-150 and 120 kDa are a
reliable indicator of recent activation of calpain and caspase-3 proteases, respectively, in
damaged neurons (reviewed by Wang, 2000). As shown in Fig. 3B, levels of all SBDPs
found in the Les-SKF mPFC were similar to control (SBDPs normalized to full-length
spectrin in Les-SKF vs. Sham-Sal, F(1,14) = 0.614, p = 0.44 for 145-150 kDa SBDPs, F(1,14)
= 0.374, p = 0.55 for 120 kDa SBDP). Finally, we examined the cytoarchitecture of cresyl
violet-stained coronal sections of the mPFC in each of the four treatment groups at 21 days
after the final dose of SKF-38393. There were no significant differences in total cell counts
across all layers of the cortex (main effect, F(3,12) = 0.971, p = 0.4385), nor in the relative
distribution of cells in the superficial vs. deep layers (Fig. 3C). Likewise, total cortical
thickness was not altered (main effect, F(3,12) = 1.206, p = 0.3494), although the thickness
of layers II/III and V was slightly redistributed in 6-OHDA-lesioned animals compared to
their sham-lesioned counterparts (Fig. 3D). In these layers, the effects of lesioning (layer II/
III, F(1,12) = 4.099, p = 0.658; layer V, F(1,12) = 0.499, p = 0.4933) and drug treatment (layer
II/III, F(1,12) = 0.063, p = 0.8056; layer V, F(1,12) = 0.155, p = 0.7004) did not reach
significance, nor was there a significant interaction of lesion condition and drug treatment
(layer II/II, F(1,12) = 0.0002, p = 0.9876).
Taken together, the results described above demonstrate that D1 priming is associated with
long-lasting changes in the dendritic appearance of MAP2 immunohistochemical staining in
the mPFC, but not with quantitative changes in MAP2 expression. The disruption of MAP2-
positive immunohistochemical profiles is often cited as an indicator of compromised
dendritic structural integrity. However, the absence of changes in immunoblotted MAP2
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profiles, markers of calcium-dependent proteolysis, total cell counts or laminar thickness
collectively suggest that widespread cellular damage or dendrite destruction do not account
for the altered appearance of MAP2 in fixed tissue sections. We therefore focused our
efforts on determining whether a qualitative change in dendrite morphology might explain
these results.
Morphological abnormalities of apical dendrites in mPFC of D1-sensitized rats
To visualize neurons and their processes directly, a recombinant AAV vector with GFP as
the transgene (McCown et al., 2006) was microinjected bilaterally into the mPFC of
neonate- and sham-lesioned rats 12 days prior to initiating treatment with SKF-38393. Using
low-power fluorescence microscopy, clusters of GFP-positive cell bodies enabled
verification that the majority of placements were made in layer V, although a few layer II/III
cells could be identified. Most of the GFP-expressing cells were consistent morphologically
with pyramidal neurons. Conspicuous apical dendrites could be visualized extending from
deeper layers well into layer I (Fig. 4A), however basal dendrites were more difficult to
distinguish due to the close arrangement of fluorescent somata and fainter intensity of GFP
expression in basal areas. Somal size, although not measured, did not appear to be affected
by treatment. Compared to mPFC neurons of Sham-SKF rats, apical shafts of Les-SKF cells
originating in layers II/III and V appeared to be wavier and somewhat disorganized.
Dendritic spines were sometimes observed along primary dendrite shafts and oblique
branches (Fig. 4B), although differences in GFP-positive spine number and morphology in
Les-SKF vs. control groups were not discernable. When sections from GFP-expressing
animals were immunostained for MAP2, we observed colocalized fluorescence
predominately in larger dendritic shafts and branches depending on the intensity of GFP
expression, and an absence of MAP2 in spines (Fig. 4C).
Although the close clustering and low fluorescence intensity of basal processes precluded
obtaining Golgi stain-like images for a full analysis of the dendritic tree, we were able to
assess several aspects of apical dendrite morphology qualitatively and quantitatively using
confocal images of single optical sections, and images reconstructed from stacks of optical
sections spaced 1 μm apart. As shown in Fig. 4D.a, apical dendrites of Sham-SKF controls
typically could be traced for nearly their entire length in single optical sections, a feature
indicative of outgrowth in a straight path. In stacked projections (Fig. 4D.b), these dendrites
appeared relatively straight and thick and were present in distinct bundles. In contrast,
dendrites in single optical section images of Les-SKF rat mPFC appeared shortened and
irregular (Fig. 4E.a), similar to their appearance when immunostained for MAP2. While
bent dendrites in single sections could be seen to deviate from linearity in the x-y plane,
waviness also occurred along the z-axis. Thus, only by changing the microscope focus
through several different planes could these dendrites be followed from the soma to the pial
surface. This is shown by stacking optical sections into projected images, revealing that
dendrites that had appeared to be shortened in single sections were actually long and wavy,
and followed a complete but meandering course toward layer I (Fig. 4E.b).
Photomicrographs similar to Figs. 4D & E were evaluated to compare quantitatively the
degree of dendrite undulation in lesioned and sham rats treated with SKF-38393. Primary
dendritic shaft lengths were measured along their visible contours within layer II/III. The
linear distance between each end was also measured and a linearity index (LI) for each shaft
was calculated as the ratio of the contour length to the end-to end length for each dendrite
(Table 1). Whereas the average LI of primary apical dendrite shafts from Sham-SKF rats
was close to 1 (or nearly linear), the LI of apical shafts from Les-SKF rats was considerably
higher. Thus while the average measurements of contour and end-to-end lengths were
similar between the two groups, dendritic shafts from Les-SKF rat mPFC deviated
substantially from linearity and were significantly different from those of Sham-SKF. The
Papadeas et al. Page 10













waviness of primary dendritic shafts was not globally present throughout the entire apical
tree, as the LI of layer I branches and oblique dendrites in layers II/III and V remained
unchanged. Instead, we observed a significant increase in the diameter of smaller branches
in Les-SKF layers I and II/III (Table 1), a finding that appeared to correspond with the
coarse and thickened MAP2 immunofluorescent staining of dendrites at the interface of
layers I and II and within the neuropil of layer II/III (see Fig. 2H). In contrast, the average
diameter of primary apical segments was not affected by D1 priming.
ERK1/2 phosphorylation may play a role the development of morphological dendritic
changes in mPFC of rats sensitized to a D1 agonist
Elevated phospho-ERK immunostaining is extraordinarily prolonged in pyramidal neurons
of D1-primed rat mPFC, and coincides with a long-lasting enhancement of CREB
phosphorylation in this region (Papadeas et al., 2004). Among the brain regions exhibiting
sustained ERK phosphorylation, the mPFC was distinct in that phospho-ERK remained
significantly elevated above baseline as long as 36 days after the final dose of D1 agonist. In
addition, a single dose of SKF-38393 at day 36 fully and stably restored phospho-ERK
immunoreactivity to maximum levels in mPFC, but was less effective in other regions.
Considering that ERK1/2 phosphorylation reflects a neuronal response to extracellular
stimulation, these findings suggest that the mPFC is exceptionally sensitive to the neural-
activating effects of D1 priming. Since MAP kinases such as ERK participate in neural
activity-dependent dendrite growth and morphology (Miller and Kaplan, 2003; Hickmott
and Ethell, 2006), we investigated whether the D1 priming-induced changes in dendrite
morphology might be associated with persistent ERK phosphorylation in the mPFC of these
animals.
In order to intensify phospho-ERK staining and enhance visualization of immunoreactive
elements, an antigen retrieval method was employed prior to immunohistochemical staining.
The overall intensity of phospho-ERK staining in neuron cell bodies, dendrites and neuropil
was amplified by antigen retrieval in both Les-SKF (Fig.5A and A’) and Sham-SKF (Fig.
5B and B’) mPFC sections. Consistent with the results of our previous study (Papadeas et
al., 2004), a pronounced increase in the number of phospho-ERK-positive cell bodies was
found at day 7 in superficial and deep layers of mPFC of Les-SKF rats. Furthermore,
enhancing the immunoreactivity of dendrites highlighted an increase in the number of
phospho-ERK-positive apical shafts in the Les-SKF group compared to Sham-SKF rats.
Many of these shafts were noticeably wavy (Fig. 5B, arrows), suggesting that at least some
of the neurons that were morphologically abnormal were also phospho-ERK-positive. There
was also a striking increase in dendritic phospho-ERK immunolabeling of layer I apical tufts
in Les-SKF mPFC (Fig. 5B’, arrowheads) compared to that of Sham-SKF animals.
Preadsorption of the antibody with phosphorylated immunizing peptide (see Methods)
completely blocked immunostaining in tissue sections subjected to the antigen retrieval
protocol (Fig. 5C), while the non-phosphorylated peptide was without effect (Fig. 5C’).
If the altered morphology of dendrites in D1-sensitized mPFC were linked to sustained
activation of ERK1/2, it might be expected that inhibition of the MEK/ERK signaling
pathway would affect the development of the morphological changes. To test this
hypothesis, we utilized two structurally and mechanistically dissimilar inhibitors of
MEK1/2, PD98059 and SL327, administered icv 30 min prior to each weekly systemic dose
of SKF-38393. As shown in Fig. 5D, icv administration of either PD98059 or SL327 prior to
each dose of SKF-38393 inhibited the increase in phospho-ERK-positive cell counts
(immunostained using the standard method without antigen retrieval) in mPFC of Les-SKF
rats. In contrast, none of the treatments had any effect on the number of phospho-ERK-
containing cells found in Sham-SKF rats.
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The effect of MEK1/2 inhibitor pretreatment on MAP2 immunostaining was next examined
in sections adjacent to those stained for ERK1/2. Preinfusion with either MEK1/2 inhibitor
prevented the D1 priming-induced alterations in MAP2 immunostaining in mPFC (compare
preinfusion with vehicle, Fig. 5E, to preinfusion with SL327, Fig. 5E’). To quantify these
findings, photomicrographs of layer II/III MAP2 immunoreactivity were used to calculate
the visible area that was linear in character, represented as a fraction of the total area (linear
area fraction). This method confined the area fraction measurement to only those elements
that resembled apical dendrite shafts, thus quantifying the “appearance” of shortened visible
dendrites in D1-primed rats. As shown graphically in Fig. 5F, the MAP2 linear area fraction
in Sham-SKF rats was not altered by preinfusion, whether the rats received 1% DMSO
vehicle (Sham-Veh-SKF), or either of the MEK inhibitors dissolved in vehicle. However, in
Les-SKF rats preinfused with vehicle (Les-Veh-SKF), the linear area fraction was decreased
by 40 to 50%, indicating that linear MAP2-immunostained profiles in Les-Veh-SKF mPFC
occupied a smaller fraction of the total stained area. On the other hand, when Les-SKF rats
were preinfused with either SL327 or PD98059, the linear area fraction of apical dendrites in
layer II/III was similar to that of the sham controls. These findings suggested that the apical
dendrite irregularities that resulted in the shortened appearance of dendrites (due to
undulations above and below the visible plane) were prevented by inhibition of the
MEK1/2-ERK1/2 signaling pathway.
To assess directly the effects of MEK1/2 inhibitors on the architectural changes in D1-
primed mPFC, we administered the systemically bioavailable inhibitor SL327 (100 mg/kg
ip) to GFP-transduced rats prior to each weekly injection of D1 agonist, and examined
dendrite morphology at 7 days after the last treatment. Systemic administration of the MEK
inhibitor alone did not affect the architecture of dendrites in the mPFC of neonate- or sham-
lesioned rats (not shown). Likewise, dendritic morphology was not altered in sham-lesioned
rats injected systemically with SL327 prior to each dose of SKF-38393 (Sham-sSL-SKF,
Fig. 6A). On the other hand, the loss of bundling and tortuous path of dendrites in the mPFC
of Les-SKF rats was prevented by SL327 (compare Les-sVeh-SKF, Fig. 6B, to Les-sSL-
SKF, Fig.6C). Quantitative analysis of photomicrographs from these animals (Fig. 6D)
revealed that SL327 prevented the D1 priming-mediated increase in the tortuosity of primary
dendrites, as measured by the calculating the linearity index as described above. In addition,
the increased diameter of layer I dendritic branches was inhibited in Les-sSL-SKF rat
mPFC, and the diameter of layer II/III oblique dendrites was significantly reduced by the
SL327 pretreatment (Fig. 6E). These findings suggest that the MEK1/2-ERK1/2 signaling
pathway may be involved in promoting the altered morphology of mPFC neurons in D1
agonist-primed rats.
DISCUSSION
Previously, we have shown that developmental lesioning of dopaminergic fibers interacts
with repeated exposure to a D1 agonist to produce neuroadaptive changes in several
corticolimbic brain regions, with a remarkably protracted enhancement of ERK
phosphorylation in the prefrontal cortex (Papadeas et al., 2004). Here, we have extended
these findings by describing long lasting changes in the morphology of pyramidal neuron
apical dendrites that is coexistent with ERK hyperphosphorylation in the mPFC of D1-
primed rats. Whereas in normal animals, long primary dendritic trunks were arranged in a
characteristic parallel, bundled pattern thought to represent pyramidal neuron functional
modules (Rockland and Ichinohe, 2004; but see below), this bundling pattern was disrupted
in D1-primed rat mPFC. Although apical dendritic shafts of layer V pyramidal neurons
maintained a general trajectory toward the pial surface, they undulated irregularly as they
coursed through layer II/III. The diameter of these primary dendritic shafts was unchanged,
however their bifurcating branches at the layer I border and higher order oblique branches
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within layer II/III were thickened. These structural changes were not found in the prefrontal
cortices of neonate-lesioned rats treated with saline or in the mPFC of sham-lesioned rats
treated with either SKF-38393 or saline. Furthermore, the effects of D1 priming on dendritic
structure in the mPFC were stable for at least three weeks after the final dose of SKF-38393,
without changes in neuron cell count, laminar thickness, or in the abundance of visible
primary shafts and higher order dendrites. Similar to controls, several dendritic processes of
D1-primed rats were studded with spines that appeared ostensibly normal, although further
experiments will be required to adequately describe dendritic spines in these animals.
The role of pyramidal neuron apical dendritic bundling in the modular organization of the
neocortex continues to be debated (Gabbot and Bacon, 1996; Rockland and Ichinohe, 2004;
Krieger et al., 2007), thus it is difficult to say what implications the loss of bundling may
have in the mPFC of the D1-primed rat. Because the electrical conductance of pyramidal
neurons is closely associated with dendrite diameter and branching patters (Holmes 1989;
Mainen and Sejnowski, 1996; Vetter et al., 2001), it is tempting to speculate that the
dendrite caliber changes we observed might cause, or might be reflective of, functional
changes in the signaling properties of these neurons. The lack of early indicators of
neurodegeneration such as dendritic swelling, beading or markers of proteolytic activity,
combined with the maintenance of dendritic spines and increased diameter of oblique
dendrites, suggest that the structural effects we observed in D1-primed rats represent an
adaptive or maladaptive response to an altered signaling environment in the mPFC, rather
than a pathological indication of outright neurotoxicity. Alternatively, these observations
might represent a snapshot of a neural effect that bears the potential to become either
progressively degradative with continued agonist dosing, or improved over time in the
absence of further stimulation. The sustained increase in immunoreactivity for
phosphorylated CREB (Papadeas et al., 2004) and ERK in affected neurons suggests that the
neurons retain their capacity to orchestrate signaling processes, and likely, gene
transcription. Along these lines, it is interesting that that plasticity and pathology are
proposed to be closely linked by a continuum of interrelated and often indistinguishable
signaling events (McEachern and Shaw, 1999; Arendt, 2004; Mattson, 2007).
While the involvement of ERK1/2 in neuronal injury (Stanciu et al., 2000; Chu et al., 2004)
and neuroprotection (Kaplan and Miller, 2000) is widely appreciated, recent studies propose
additional roles for ERK in the regulation of dendritic structure and plasticity (Miller and
Kaplan, 2003; Sweatt 2004; Chen and Ghosh, 2005). Cortical pyramidal neurons of
transgenic mice expressing a constitutively active form of the upstream MEK/ERK activator
p21H-ras display enhanced dendritic length, diameter and complexity (Alpar et al., 2003), as
well as an increase in the phosphorylation of cytoskeletal proteins by ERK1/2 (Holzer et al.,
2001). Furthermore, in primary neuronal cultures and tissue slices, ERK1/2 has been shown
to mediate activity-dependent changes in dendrite structure (Quinlan and Halpain, 1996b;
Wu et al., 2001; Vaillant et al., 2002). In the present study, the hypothesis that the
morphological effects observed in mPFC dendrites of D1-primed rats are related to
persistent ERK hyperphosphorylation in this region is supported by several lines of
evidence. First, D1 agonist dosing was required to produce both the prolonged ERK
phosphorylation and the dendritic transfiguration in neonate-lesioned rats. Second, the
dendritic changes were temporally coincident with ERK phosphorylation, at least within the
first 21 days after the end of the priming regimen. Third, many phospho-ERK-positive
primary dendritic shafts that were traceable over some distance were conspicuously wavy.
Most importantly, the administration of a MEK inhibitor prior to each dose of D1 agonist
precluded the changes in dendrite structure that occurred due to D1 priming.
Both PD98059 and SL327 are selective inhibitors of the obligate upstream activator of
ERK1/2, MEK1/2 (Alessi et al., 1995; Favata et al., 1998; Blum et al., 1999; Valjent et al.,
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2000; Pearson et al., 2001). It has been proposed that U0126 (the parent compound of
SL327) and PD98059 inhibit MEK by different mechanisms (Favata et al., 1998; but see
Davies et al., 2000). These agents have distinct chemical structures and favorable, though
slightly different selectivity profiles in vitro (Davies et al., 2000). Thus it is likely that the
effects of these compounds in the present study were mediated by MEK1/2 inhibition and
not by some common, nonspecific mechanism. Moreover, we found that these agents were
similarly effective whether administered icv (in the case of PD98059 or SL327), or
systemically (SL327). Taken together our findings suggest that ERK-related signaling may
play a role in establishing and/or maintaining the persistent changes observed in mPFC
dendrite morphology. Relating to this, preliminary studies indicate that a single dose of a
MEK inhibitor, administered only following the final dose of SKF-38393, ameliorates the
decreases in quantitative measures of MAP2 immunostaining observed with D1 priming (not
shown). Continuous activity by MEK1/2 may thus be required in order to maintain these
structural adaptations over time.
A considerable portion of cellular ERK associates with the cytoskeleton (Fiore et al., 1993;
Reszka et al., 1995). ERK1/2 may associate with microtubules and other cytoskeletal
elements without directly phosphorylating them, an interaction that could serve to scaffold
the ERK signaling pathway to facilitate its activity, or retain active ERK within the
cytoplasm (Morishima-Kawashima and Kosik, 1996; Reszka et al., 1995). Within the
dendritic cytoskeleton, phosphorylation by ERK1/2 regulates the function of many of its
substrates, including MAP1, -2, and -4, neurofilament proteins and stathmin. The
phosphorylation of MAP2 by ERK1/2 results in destabilization of dendritic microtubules
(Sanchez et al., 2000). Such destabilization might provide one explanation for the
appearance of apical dendrites in D1-primed rats. Several kinases, including glycogen
synthase kinase (GSK), calcium/calmodulin-dependent kinases (CAMKs), the MAP kinases
JNK and p38, PI3-kinase and many others, cooperate in an upstream or parallel fashion with
ERK1/2 to regulate cytoskeletal elements and thus affect dendrite morphology (Redmond et
al., 2002; Vaillant et al., 2002 Chang et al., 2003; Miller and Kaplan, 2003; Dijkhuizen and
Ghosh, 2004; Hickmott and Ethell, 2006). Further studies will be necessary to delineate the
exact mechanism by which sustained ERK activation supports the adaptations observed in
the mPFC of D1-primed rats.
Immunolabeling with anti-MAP2 is frequently used as a marker for somatodendritic
structures, based on its preferential expression in dendrites and neuron cell bodies, and on
evidence that dendritic growth correlates with an increase in MAP2 immunostaining
(Philpot et al., 1997; Sanchez et al., 2000; Bury and Jones, 2002). However, our findings
suggest that some caution is necessary when interpreting MAP2 immunostaining in fixed
tissue sections. Anti-MAP2 labeled large caliber primary shafts more effectively than
smaller dendrites, and the waviness of these large shafts was reflected
immunohistochemically as shortened and bent profiles in D1-primed rats. By confocal
reconstruction of GFP-expressing dendrites, we demonstrated that these dendrites were not
shortened, but rather disappeared from the plane of view due to optical and physical
sectioning of the tissue. Similarly, the diminished appearance of MAP2 immunostaining in
the mPFC was not corroborated quantitatively by western blotting, but instead might be
attributed partially to the loss of bundling and increased spacing between primary dendritic
shafts. In the neuropil, MAP2-labeled oblique dendrites that were detected colorimetrically
with DAB were less visible than when the same antibody was detected by fluorescence
methods. Differences in secondary antibody affinity or greater optical sensitivity of the
instrumentation for fluorescence detection might account for this discrepancy. Nevertheless,
these results emphasize that careful scrutiny of MAP2 immunoreactive profiles and
complementary methodology are critical to avoid misinterpretation of MAP2 findings in
tissue sections.
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The wavy, disorganized appearance of mPFC apical processes in D1-primed rats bears a
strong morphological resemblance to the loss of bundling and irregularly shaped dendrites
observed in the frontal cortices of prenatal cocaine-exposed animals (Jones et al., 1996;
Murphy et al., 1997; Stanwood et al., 2001) and D1 receptor knockout mice (Stanwood et
al., 2005). While these structural similarities and the involvement of dopaminergic signaling
might invite mechanistic comparisons however, the effects are distinguishable temporally
from those of adult D1 primed rats. Disruption of dendritic profiles has been shown to be
present from embryonic development in prenatal cocaine-treated animals (Jones et al.,
2000), and from the early postnatal period in D1 receptor-null mice (Stanwood et al., 2005),
and is maintained into adulthood. This implies that during morphogenesis, turning growth
cones responded to prevailing neurotransmitter activity by altering dendrite trajectories
(Levitt et al., 1997). In contrast, mPFC pyramidal dendrites in 6-OHDA neonate-lesioned
rats are normal in appearance until the animals are exposed to a D1 agonist in adulthood;
afterwards, the effects of agonist administration are maintained for several weeks following
the cessation of drug treatment. These findings suggest that, like the behavioral expression
of D1 priming, a latent susceptibility for morphological disruption is established by
dopamine loss during development. While homeostatic mechanisms may conceal certain
behavioral and structural phenotypes in rats that undergo development without dopamine
from the early postnatal period, the vulnerability for such changes to occur persists into
adulthood. Subsequent exposure to a dopaminergic agonist interacts with or unmasks the
potential for these outcomes, which are then manifested in an enduring manner. Within the
neural circuitry that subserves dopaminergic sensitization, D1 agonist treatment stimulates
long-lasting alterations in neurochemical signaling, likely contributing to the stability of
these effects.
Recent evidence implicates an interacting relationship between dopamine dysregulation,
behavioral and biochemical sensitization, and environmental factors such as stress or drug
exposure in the pathophysiology of several disorders involving frontostriatal circuit
dysfunction (see, for example, Howes et al., 2004, and Visser et al., 2000). In Lesch-Nyhan
syndrome (LNS) for example, reduced dopaminergic neuron density in the caudate-putamen
and alterations in receptor sensitivity are evident early in life. Interestingly however,
aggressive behavior in 10 to 20 year old Lesch-Nyhan patients has been correlated with
somewhat higher residual presynaptic dopamine activity (Ernst et al., 1996). Although
speculative, some of the behavioral manifestations of LNS might thus represent a sensitized
response to remaining dopamine, the release of which would be subject to stimulation by
stress and other external conditions. Similar behaviorally as well as neurochemically to
LNS, the D1-primed rat exhibits latent, environmentally activated (by D1 agonist
administration) hyperresponsiveness as a result of developmental dopamine loss, thus
modeling critical features of LNS and other frontostriatal circuit disorders (Breese et al.,
2004). Furthermore, consistent with our own studies, changes in prefrontal dendrite
morphology have been identified in other animal models of these disorders (Wedzony et al.,
2005; Flores et al., 2005; Mikolaenko et al., 2005; Robinson and Kolb, 2004). It is
reasonable to suggest that prefrontal cortical dendritic remodeling in such disorders might
reflect both consequence and cause: as an adaptation to developmental or chronic alterations
in functional circuitry, and as a contributor to the behavioral impairments associated with
them, respectively. The relationship between the behavioral effects of D1 priming and
dendritic changes in the mPFC will be the subject of future investigations.
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Experimental timelines for animal treatments and analyses. For each study, the number of
experimental subjects is provided in parentheses, and tissue analyses performed post-
sacrifice are indicated on the right. All experiments consisted of 6-OHDA or sham lesioning
on PND 4, followed by behavioral priming with weekly treatments of SKF-38393 or saline
beginning at PND 42 (arrows over darkened band). Locomotor activity was monitored
immediately following each dose. Seven days after the final treatment, animals were
perfused transcardially (S), except for a subset of subjects in study A that were sacrificed on
PND 84 (21 days after the final dosing, as indicated with an asterisk). In B, cannula
implantation (CI) was performed on PND 35 to prepare for preinfusions with MEK
inhibitor. Preinfusions were administered 30 min prior to each weekly dose of SKF-38393.
To transduce neuronal GFP expression, rats in 2 studies (C and D) received prefrontal
cortical injections of AAV-GFP at PND 30 (GFP), followed by agonist dosing beginning on
PND 42. In study D, animals expressing GFP were pretreated with systemic injections of
SL-327, 30 min before each dose of SKF-38393.
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MAP2 immunohistochemistry is altered in mPFC of D1-primed rats. Roman numerals
indicate approximate location of cortical layers. All animals were euthanized 7 d after the
last dose of SKF-38393 or saline except where indicated. (A) Representative mPFC section
from a sham-lesioned rat treated with weekly injections of saline (Sham-Sal). (B) Higher
power image from the same region in a sham-lesioned rat treated with weekly injections of
SKF-38393 (Sham-SKF). (C) Neonate-lesioned rat treated with weekly injections of saline
(Les-Sal). (D, E) Lesioned rat treated with weekly injections of SKF-38393 (D1-primed,
Les-SKF). (F) MAP2 in a Les-SKF rat euthanized 21 d after the final dose of SKF-38393.
(G, H) Confocal images of MAP2 immunofluorescence in Sham-SKF and Les-SKF rat
mPFC, respectively. Note the coarser, more granular appearance of punctate elements in the
neuropil of primed rats (arrows in H), and the thickening of dendritic branches at the
interface of layers II/III and I (arrowheads in H) compared to those of control rats. (I)
Schematic diagram of region of interest, adapted from Paxinos and Watson (1998). Gray
box represents area depicted in A and D. (J) MAP2 immunostaining in Les-SKF visual
cortex was unaltered. Scale bars for A, D and J, 100 μm. Scale bars for B, C and E-H, 50
μm. Note: a magenta-green version of this figure can be viewed online as Supplementary
Figure 1.
Papadeas et al. Page 21














MAP2, αII-spectrin, total cell counts and cortical thickness are all unchanged in mPFC of
D1-primed rats. (A) Representative Western blot of MAP2 and β-actin in mPFC of
SKF-38393-treated sham (Sham-SKF) and lesioned rats (Les-SKF) and their saline-treated
counterparts (Sham-Sal and Les-Sal, respectively). Faint bands in the center of each lane are
consistent with MAP2 degradation products. (B) Spectrin and its breakdown products
(SBDPs) in mPFC homogenates from Sham-Sal and Les-SKF rats. Neither the 145-150 kDa
calpain-mediated cleavage products, nor the 120 kDa caspase-3 SBDP were altered by D1
priming. (C) Cresyl violet-stained neurons counted at day 21 after dosing across superficial
(I-III) and deep (V-VI) mPFC layers. Data are expressed as percent of total cell counts
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across all layers: black bars, Sham-Sal, 4810.5 ± 130.7 total cells; dark gray bars, Sham-
SKF, 4237.7 ± 289.2 cells; white bars, Les-Sal, 4781.0 ± 441.9 cells; light gray bars, Les-
SKF, 4326.5 ± 269.2 cells counted across all layers. (D) Mean cortical layer thickness at day
21 plotted as percent of total mPFC thickness. Filled squares, Sham-Sal; filled circles,
Sham-SKF; open squares, Les-Sal; open circles, Les-SKF.
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Confocal imaging of mPFC neurons transduced with AAV-GFP. (A) Clusters of fluorescent
neurons surrounding the injection site in Sham-SKF mPFC. Prominent first order dendrites
were long and straight, branching into tufts at the interface of layers II/III and I. (B)
Representative high power image of GFP-positive dendrites in mPFC of a Les-SKF rat
sacrificed at day 7 after the priming regimen. Arrows indicate the presence of dendritic
spines. (C) Overlay of the image in B with the corresponding image of MAP2
immunofluorescence showing colocalization in larger dendritic shafts but not in spines
(arrows). (D) Image of a single 1 μm optical section (D.a), and the corresponding
reconstructed projection of 10 optical sections (D.b), of Sham-SKF mPFC. Most dendrites
are visible along their entire length in both single slice images and projections (indicated by
arrowheads). (E) Single 1 μm optical section (E.a), and corresponding stacked
reconstruction (E.b), of dendrites in Les-SKF mPFC. Several dendrites disappeared out of
the single section images (arrowheads in E.a), and could only be followed for their entire
length by stacking multiple images as shown in E.b. Scale bar for A, 50 μm. Scale bar for B-
E, 20 μm. Note: a magenta-green version of this figure can be viewed online as
Supplementary Figure 2.
Papadeas et al. Page 24














Sustained ERK phosphorylation may contribute to mPFC morphological abnormalities in
D1-primed rats. Antigen retrieval was used to intensify phospho-ERK staining in Sham-SKF
(A and A’) and Les-SKF (B and B’) mPFC. Note the wavy phospho-ERK-positive dendritic
shafts (arrows) and enhanced immunostaining of dendrite apical tufts (arrowheads) in
sections from Les-SKF (D1-primed) rat mPFC compared to that of Sham-SKF. Scale bars,
200 μm. Specificity of the antibody under antigen retrieval conditions is shown by abolition
of staining using a phosphorylated (C), but not a non-phosphorylated (C’) blocking peptide.
(D) MEK inhibitors administered prior to each weekly dose of SKF-38393 prevented the
sustained increase in phospho-ERK observed at day 7 in D1-primed rats. Sham-lesioned
(filled bars) and neonate-lesioned (open bars) animals were administered icv infusions of
vehicle, PD98059 or SL327, 30 min before each weekly systemic injection of SKF-38393.
Cell counts were obtained from mPFC sections immunostained for phospho-ERK without
antigen retrieval and represent total counts across all cortical layers. Represented are means
± S.E.M. ** p < 0.0001 vs. sham-lesioned rats preinfused with vehicle prior to SKF-38393
(Sham-Veh-SKF); ‡‡‡ p < 0.0001 vs. D1-primed rats preinfused with vehicle (Les-Veh-
SKF). (E and E’) Representative photomicrographs of MAP2 immunohistochemistry in Les-
Veh-SKF and Les-SL-SKF mPFC, respectively. Scale bars, 50 μm. (F) Quantitative analysis
of MAP2 immunostaining using linear area fraction measurements. The format of the graph
is the same as in D. Preinfusions of either PD98059 or SL327 had no effect in sham rats
treated with SKF-38393 (filled bars), but prevented the loss of linear dendritic
immunostaining in lesioned rats that were primed with the agonist (open bars). * p < 0.001
vs. Sham-Veh-SKF; ‡‡ p < 0.001, and ‡ p < 0.05 vs. Les-Veh-SKF; ANOVA with Fisher’s
PLSD.
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Systemic treatment with SL327 prevents the structural abnormalities induced by D1-
priming. Rats were administered 100 mg/kg ip SL327 (sSL) or vehicle (sVeh), 30 min prior
to each weekly dose of SKF-38393 and sacrificed 7 days following the final treatment. (A-
C), Reconstructed confocal images of GFP-positive dendrites in Sham-sVeh-SKF (A), Les-
sVeh-SKF (B), and Les-sSL-SKF (C) rat mPFC. Scale bars, 50 μm. (D) Linearity index of
dendritic elements in GFP-expressing mPFC of Sham-sVeh-SKF (black bars), Les-sVeh-
SKF (open bars), and Les-sSL-SKF rats (gray bars). Represented are means ± S.E.M. *** p
< 0.0001 vs. Sham-sVeh-SKF. (E) Diameter of dendritic elements in mPFC. The format is
the same as in D. ** p < 0.005, and * p < 0.05 vs. Sham-sVeh-SKF; ANOVA with Fisher’s
PLSD.
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Table 1
Effects of D1 priming on linearity index and diameter of GFP-expressing dendrites in mPFC
Average Contour Measurement Average End-to-end Measurement Linearity Index Diameter
Primary shafts
  Sham-SKF 154.98 ± 3.93 154.37 ± 4.03 1.004 ± 0.001 2.44 ± 0.31
  Les-SKF 151.47 ± 6.10 148.55 ± 6.26 1.019 ± 0.002** 2.29 ± 0.40
Layer I branches
  Sham-SKF 47.93 ± 2.59 45.67 ± 2.49 1.052 ± 0.004 0.77 ± 0.06
  Les-SKF 46.69 ± 1.63 44.01 ± 1.57 1.065 ± 0.008 1.11 ± 0.09*
Layer II-III obliques
  Sham-SKF 30.16 ± 0.94 28.07 ± 0.83 1.076 ± 0.007 0.76 ± 0.02
  Les-SKF 30.31 ± 1.43 28.09 ± 1.42 1.085 ± 0.009 1.06 ± 0.12*
Layer V obliques
  Sham-SKF 24.23 ± 2.12 22.55 ± 1.88 1.075 ± 0.014 0.73 ± 0.02
  Les-SKF 27.71 ± 0.98 25.76 ± 0.83 1.077 ± 0.006 0.79 ± 0.05
To obtain the linearity index, the contour length of each dendrite was divided by the length of a straight line from one end of the dendrite to the
other. Diameter was measured at 2-3 different sites along the visible length and averaged for each dendrite. See Methods for total numbers of
dendrites measured per animal. Each measurement was averaged per animal and data are expressed as the mean ± SEM of all animals per group.




p < 0.005 vs. Sham-SKF.
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